Approved for EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.. Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat patients with spinal muscular atrophy (SMA) caused by mutations in chromosome 5q that lead to SMN protein… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from…
Loading full data from Know Your Drugs Institute…